Cancer Communications
indexed by SCI
BMC

Original article
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
Zhi-Xia Yue, Tian-Yu Xing, Chao Gao, Shu-Guang Liu, Wen Zhao, Qian Zhao, Xi-Si Wang, Mei Jin & Xiao-Li Ma
Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children Hematology Oncology Center, Beijing Children??s Hospital, Capital Medical University, National Center for Children??s Health, 56 Nanlishi Road, Beijing, 100045, People??s Republic of China
[Abstract]

Background
Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in patients with bone marrow metastatic neuroblastoma. MYCN amplification alone, however, is insufficient for pretreatment risk stratification. Chromosome band 11q23 deletion has recently been included in the risk stratification of neuroblastoma. In the present study, we aimed to evaluate the biological characteristics and prognostic impact of 11q23 deletion and MYCN amplification in patients with bone marrow metastatic neuroblastoma.
Methods
We analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic neuroblastoma using interphase FISH of bone marrow cells. We specifically compared the biological characteristics and prognostic impact of both aberrations.
Results
MYCN amplification and 11q23 deletion were seen in 12 (11.9%) and 40 (39.6%) patients. The two markers were mutually exclusive. MYCN amplification occurred mainly in patients with high lactate dehydrogenase (LDH) and high neuron-specific enolase (NSE) levels (both P < 0.001), and MYCN-amplified patients had more events (tumor relapse, progression, or death) than MYCN-normal patients (P = 0.004). 11q23 deletion was associated only with age (P = 0.001). Patients with MYCN amplification had poorer outcomes than those with normal MYCN (3-year event-free survival [EFS] rate: 8.3 ?? 8.0% vs. 43.8 ?? 8.5%, P < 0.001; 3-year overall survival [OS] rate: 10.4 ?? 9.7% vs. 63.5% ?? 5.7%, P < 0.001). 11q23 deletion reflected a poor prognosis only for patients with normal MYCN (3-year EFS rate: 34.3 ?? 9.5% vs. 53.4 ?? 10.3%, P = 0.037; 3-year OS rate: 42.9 ?? 10.4% vs. 75.9 ?? 6.1%, P = 0.048). Those with both MYCN amplification and 11q23 deletion had the worst outcome (P < 0.001).
Conclusions
Chromosome band 11q23 deletion predicts poor prognosis only in bone marrow metastatic neuroblastoma patients without MYCN amplification. Combined assessment of the two markers was much superior to single-marker assessment in recognizing the patients at a high risk of disease progression.
Cancer Communications   Epub date: 11/4/2019   doi:10.1186/s40880-019-0409-1
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Zhi-Xia Yue, Tian-Yu Xing, Chao Gao, Shu-Guang Liu, Wen Zhao, Qian Zhao, Xi-Si Wang, Mei Jin & Xiao-Li Ma. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification. Cancer Commun (Lond). 2019, 39:68. doi:10.1186/s40880-019-0409-1


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China